Credit Suisse upgraded GlaxoSmithKline (NYSE: GSK) from Underperform to Neutral. The price target is unchanged at 1440p. Analysts led ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE